Atrial natriuretic peptide: A molecular target of novel therapeutic approaches to cardio-metabolic disease

Valentina Cannone, Aderville Cabassi, Riccardo Volpi, John C Jr. Burnett

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Atrial natriuretic peptide (ANP) is a cardiac hormone with pleiotropic cardiovascular and metabolic properties including vasodilation, natriuresis and suppression of the renin-angiotensin-aldosterone system. Moreover, ANP induces lipolysis, lipid oxidation, adipocyte browning and ameliorates insulin sensitivity. Studies on ANP genetic variants revealed that subjects with higher ANP plasma levels have lower cardio-metabolic risk. In vivo and in humans, augmenting the ANP pathway has been shown to exert cardiovascular therapeutic actions while ameliorating the metabolic profile. MANP is a novel designer ANP-based peptide with greater and more sustained biological actions than ANP in animal models. Recent studies also demonstrated that MANP lowers blood pressure and inhibits aldosterone in hypertensive subjects whereas cardiometabolic properties of MANP are currently tested in an on-going clinical study in hypertension and metabolic syndrome. Evidence from in vitro, in vivo and in human studies support the concept that ANP and related pathway represent an optimal target for a comprehensive approach to cardiometabolic disease.

Original languageEnglish (US)
Article number3265
JournalInternational journal of molecular sciences
Volume20
Issue number13
DOIs
StatePublished - Jul 1 2019

    Fingerprint

Keywords

  • Atrial natriuretic peptide
  • Cardiometabolic disease
  • cGMP
  • Guanylyl cyclase receptor A
  • Heart failure
  • Hypertension
  • Metabolic syndrome
  • Natriuretic peptides
  • Obesity

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this